...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of neurology: the official journal of the European Federation of Neurological Societies >Influence of age at disease onset on future relapses and disability progression in patients with multiple sclerosis on immunomodulatory treatment
【24h】

Influence of age at disease onset on future relapses and disability progression in patients with multiple sclerosis on immunomodulatory treatment

机译：疾病症对免疫调节治疗患者未来复发和残疾进展的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background and purpose To investigate the relation of age at disease onset and clinical outcomes across the lifespan from adolescence in patients with multiple sclerosis (MS) on disease‐modifying therapy (DMT). Methods We analysed data from the Swiss Association for Joint Tasks of Health Insurers database containing data from 14?718 patients with MS. Patients were included in this analysis when they were on DMT for at least 1?year. The influence of age at disease onset on future relapses and disability worsening was explored using?multivariable Cox proportional hazard regression models. Results Data from 9705 patients with MS were analysed. Pediatric‐onset MS?patients ( n ?=?236) had higher relapse rates and marginally slower disability worsening rates compared with adult‐onset MS ( n ?=?9469). The risk of relapses was highest in childhood and decreased continuously to about 35?years of age. It remained stable for about a decade and then again continuously decreased. In contrast, disability worsening hazards remained stable from childhood to about 32?years of age and then increased sharply around the age of 45?years. Conclusions Age is an important factor independently?affecting clinical outcomes in MS. This should be considered when designing clinical trials or choosing DMT.
机译：背景和目的在疾病修饰治疗（DMT）患者中，探讨患有疾病发作和疾病发作和临床结果的疾病发作和临床结果的关系。方法，我们分析了瑞士卫生保险公司的联合任务的数据，其中包含14岁的卫生保险公司数据库的联合任务.718患者患者。当患者在DMT上纳入至少1岁时，患者包含在此分析中。利用？多变量Cox比例危险回归模型探讨了疾病发病对未来复发和残疾恶化的影响。结果分析了9705例MS患者的数据。儿科发病MS？患者（N？=？236）与成人发作MS相比，复发率较高，残疾较慢的残疾恶化率（n？= 9469）。童年中复发的风险最高，不断减少到大约35年龄。大约十年来它保持稳定，然后再次连续减少。相比之下，残疾恶化的危害从童年到大约32岁时保持稳定，然后在45岁左右增加急剧增加。结论年龄是一个独立的重要因素？影响MS中的临床结果。在设计临床试验或选择DMT时应考虑这一点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号